
Daily MailSig. 7NewsHealthLaborStocks
Wegovy maker Novo sheds 13,000 jobs as it slims down in war of the fat jabs
Novo Nordisk has shed 13,000 jobs over the past year, including 9,000 layoffs and 4,000 unfilled roles, as it faces intensifying competition from Eli Lilly in the obesity and diabetes drug market. CEO Mike Doustdar presented plans to revive growth with new drugs and expanded manufacturing, but shares fell 9% and remain far below their 2024 peak. Analyst commentary focused on investor patience and competitive positioning.










